Press Release Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity Aug 13
Press Release Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights Aug 5